Journals / Klinik Psikofarmakoloji Bülteni / 2006 / Cilt: 16 - Sayı: 2

Alzheimer hastalığı ve hafif kognitif bozuklukta pirasetamin EEG spektral analizi üzerine uzun dönem etkileri

Long term effects of piracetam on spectral analysis of EEG in Alzheimer disease and minimal cognitive impairment

Pages
93–97
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

MCI patients have shown very similar results with AD patients Conclusions: We have found that long term delivering of piracetam enhances slow-wave band powers of EEG both in Alzheimer’s disase and MCI patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Influence of piracetam in post-stroke aphasia and myoclonic epilepsy has been shown with EEG spectral power analysis.
📊
Key Findings & Data:Methods: We have evaluated spectral EEG analysis of 13 minimal cognitive impairment and 18 mild or less severe Alzheimer dementia patients after receiving piracetam 2400 mg and 4800 mg respectively for 4 weeks.
💡
Conclusion & Impact:MCI patients have shown very similar results with AD patients Conclusions: We have found that long term delivering of piracetam enhances slow-wave band powers of EEG both in Alzheimer’s disase and MCI patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Influence of piracetam in post-stroke aphasia and myoclonic epilepsy has been shown with EEG spectral power analysis. Particularly piracetam is involved in restoration of alpha topography in these patients. On the other hand long term effects of piracetam in Alzheimer’s disase or minimal cognitive impairment (MCI) patients have not been determined so far. Methods: We have evaluated spectral EEG analysis of 13 minimal cognitive impairment and 18 mild or less severe Alzheimer dementia patients after receiving piracetam 2400 mg and 4800 mg respectively for 4 weeks. Control group was consisted of 16 healthy subjects with similar age and sex characteristics. We analyzed EEG power spectrum before and after delivering 2400 or 4800 mg piracetam. Results: In Alzheimer’s disase group enhancement of delta band power began with 2400 mg piracetam and lasted on 4800 mg. Theta band power spectrum values significantly decreased. Alpha and beta band power spectrums were not changed. MCI patients have shown very similar results with AD patients Conclusions: We have found that long term delivering of piracetam enhances slow-wave band powers of EEG both in Alzheimer’s disase and MCI patients.

Özet

Amaç: Piracetamın inme sonrası afazi ve miyoklonik epilepside etkileri EEG’de spektral güç analizleri ile gösterilmiştir. Bu hastalarda pirasetamı n kısmen alfa topografisinde düzenlenmesinde rolü olduğu bildirilmesine rağmen Alzheimer hastalarında veya hafif kognitif bozukluğu olan hastalarda pirecetamın uzun süreli etkileri tam olarak tanımlanmamıştır.Yöntem: Bu çalışmada 13 hafif kognitif bozukluğu olan hasta, 18 hafif veya orta derecede Alzheimer hastası ve bu hastalara yaş ve cinsiyet olarak benzer özelliklere sahip 16 sağlıklı bireyden oluşan kontrol grubunda başlangıç, 4 hafta süre ile 2400 mg piracetam kullanımı ve bunu takip eden 4 hafta süre ile 4800 piracetam kullanımı sonrası spektral EEG kayıtları incelenerek güç spektrumu analizleri yapılmıştır.Sonuçlar: Alzheimer grubunda delta bant gücünün 2400 mg dozunda ortaya çıktığı ve bu durumun 4800 mg dozunda da devam ettiği görülmüştür. Teta bant gücünde anlamlı olarak azalmanın ortaya çıktığı, alfa ve beta bant güçlerinde ise değişikliğin ortaya çıkmadığı saptanmı ştır. Hafif kognitif bozukluğu olan hastalarda da benzer sonuçlar elde edilmiştir.Sonuç:Uzun süreli piracetam kullanımın Alzheimer hastaları ve hafif kognitif bozukluğu olan hastalarda EEG’de yavaş dalga bant güçlerini arttırmaktadır.

🔖

Cite This Article

ŞAHİNER, M., ERDOĞAN, Ç., ŞAHİNER, T., GÜR, S., DEĞİRMENCİ, E., ÖZDEMİR, F. (2022). Alzheimer hastalığı ve hafif kognitif bozuklukta pirasetamin EEG spektral analizi üzerine uzun dönem etkileri. Klinik Psikofarmakoloji Bülteni, Cilt: 16 - Sayı: 2, 93–97. https://ajindex.com/articles/574417

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Waegemans T, Wilsher CR, Danniau A, Ferris SH, Kurz A, Winblad B. Clinical efficacy of piracetam in cognitive impairment: a metaanalysis. Dement Geriatr Cogn Disord 2002;13:217-224 2. Croisile B, Trillet M, Fondarai J, Laurent B, Mauguiere F, Billardon M. Long-term and highdose piracetam treatment of Alzheimer's disease. Neurology 1993; 43:301-305 3. Sannita WG, Balestra V, Rosadini G, Salama M, Timitilli C. Quantitative EEG andneuropsychological effects of piracetam and of the association piracetam-lecithin in healthy volunteers. Neuropsychobiology 1985;14:203-209 4. Kinoshita T. Quantitative pharmaco-EEG study of nootropics. Seishin Shinkeigaku Zasshi 1990;92:255-276 5. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989:39:1159-1165 6. Güngen C, Ertan T, Eker E, Yaşar R, Engin F: The Standardized Mini Mental State Examination in Turkish. 9th Congress of The International Psychogeriatric Association, August 15-20,
  2. Vancouver, Canada, 1999 7. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364 8. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale (GDS) for assessment of primary degenerative dementia. Am J Psychiatr 1982;139:1136-1139 9. Pierlovisi-Lavaivre M, Michel B, Sebban C, Tesolin B, Chave B, Sambuc R, Melac M, Gastaut JL, Poitrenaud J, Millet Y. The significance of quantified EEG in Alzheimer's disease. Changes induced by piracetam. Neurophysiol Clin 1991;21:411-423 10. Moran TH, Capone GT, Knipp S, Davisson MT, Reeves RH, Gearhart JD. The effects of piracetam on cognitive performance in a mouse model of Down's syndrome. Physiol Behav 2002;77:403-409 11- Eckert GP, Cairns NJ, Muller WE. Piracetam reverses hippocampal membrane alterations in Alzheimer's disease. J Neural Transm 1999;106:757-761 12. Mindus P, Cronholm B, Levander SE, Schalling D. Piracetaminduced improvement of mental performance. A controlled study on normally aging individuals. Acta Psychiatr Scand 1976;54:150-160 13. Wackermann J, Lehmann D, Dvorak I, Michel CM. Global dimensional complexity of multichannel EEG indicates change of human brain functional state after a single dose of a nootropic drug. Electroencephalogr Clin Neurophysiol 1993;86:193-198 14. Kondakor I. Effects of piracetam on the cognitive